[go: up one dir, main page]

MXPA02005562A - Superdesintegrante farmaceutico. - Google Patents

Superdesintegrante farmaceutico.

Info

Publication number
MXPA02005562A
MXPA02005562A MXPA02005562A MXPA02005562A MXPA02005562A MX PA02005562 A MXPA02005562 A MX PA02005562A MX PA02005562 A MXPA02005562 A MX PA02005562A MX PA02005562 A MXPA02005562 A MX PA02005562A MX PA02005562 A MXPA02005562 A MX PA02005562A
Authority
MX
Mexico
Prior art keywords
superdisintegrant
superdisintegrants
dosage form
solid dosage
compactibility
Prior art date
Application number
MXPA02005562A
Other languages
English (en)
Inventor
Staniforth John
Original Assignee
Penwest Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Penwest Pharmaceuticals Co filed Critical Penwest Pharmaceuticals Co
Publication of MXPA02005562A publication Critical patent/MXPA02005562A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se describen superdesintegrantes los cuales proporcionan compresabilidad mejorada en comparacion con los superdesintegrantes de la tecnica anterior que no tienen un impacto negativo sobre la compresabilidad de formulaciones que incluyen farmacos en altas dosis, y metodos para obtener los mismos. Los superdesintegrantes incluyen un aglomerado particulado de almidon o celulosa coprocesada y una cantidad suficiente de un agente aditivo para incrementar la compactabilidad del superdesintegrante. El superdesintegrante aumentado proporciona una desintegracion rapida de una forma de desintegracion solida cuando se incorpora en una cantidad suficiente homologa, sin afectar de manera adversa la compactabilidad de la forma de dosificacion solida (en relacion a una forma de dosificacion solida sin el superdesintegrante).
MXPA02005562A 1999-12-06 2000-12-06 Superdesintegrante farmaceutico. MXPA02005562A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16917499P 1999-12-06 1999-12-06
PCT/US2000/032989 WO2001039746A1 (en) 1999-12-06 2000-12-06 Pharmaceutical superdisintegrant

Publications (1)

Publication Number Publication Date
MXPA02005562A true MXPA02005562A (es) 2004-09-10

Family

ID=22614504

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA02005562A MXPA02005562A (es) 1999-12-06 2000-12-06 Superdesintegrante farmaceutico.

Country Status (11)

Country Link
US (2) US6660303B2 (es)
EP (1) EP1244428A1 (es)
KR (1) KR20020062323A (es)
AU (2) AU771440B2 (es)
BR (1) BR0016482A (es)
CA (1) CA2393231A1 (es)
HU (1) HUP0301333A3 (es)
IL (1) IL150053A0 (es)
MX (1) MXPA02005562A (es)
NO (1) NO20022645L (es)
WO (1) WO2001039746A1 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0204771D0 (en) * 2002-02-28 2002-04-17 Phoqus Ltd Fast disintegrating tablets
AU2003256284A1 (en) * 2002-06-20 2004-01-06 Orapharma, Inc. Rapidly disintegrating formulations for treating or preventing mucositis
SI21221A (sl) * 2002-06-21 2003-12-31 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Hitro razpadljive tablete
US20040265375A1 (en) * 2003-04-16 2004-12-30 Platteeuw Johannes J. Orally disintegrating tablets
EP1694300A4 (en) * 2003-12-09 2009-04-29 Pharmasset Inc DOSAGE PROCESS FOR BETA-D-2 ', 3'-DIDEOXY-2', 3'-DIDEHYDRO-5-FLUOROCYTIDINE ANTIVIRAL THERAPY
ATE403418T1 (de) * 2004-03-10 2008-08-15 Ranbaxy Lab Ltd Verfahren zur herstellung von festen dosierformen von amorphem valganciclovir-hydrochlorid
US20050220865A1 (en) * 2004-04-02 2005-10-06 Koleng John J Compressed composition comprising magnesium salt
JP2007532623A (ja) * 2004-04-12 2007-11-15 ファイザー・プロダクツ・インク 破裂型多重粒子中の味マスキング薬物
ES2550626T5 (es) 2005-02-25 2019-01-15 Takeda Pharmaceuticals Co Método para producir gránulos
US20080020040A1 (en) * 2006-07-18 2008-01-24 Horizon Therapeutics, Inc. Unit dose form for administration of ibuprofen
JP2009501801A (ja) * 2005-07-18 2009-01-22 ホライゾン セラピューティクス， インコーポレイテッド イブプロフェンとファモチジンとを含有する医薬およびその投与
US8067451B2 (en) * 2006-07-18 2011-11-29 Horizon Pharma Usa, Inc. Methods and medicaments for administration of ibuprofen
US8067033B2 (en) * 2007-11-30 2011-11-29 Horizon Pharma Usa, Inc. Stable compositions of famotidine and ibuprofen
EP2091519B1 (en) * 2006-11-30 2015-06-24 Bend Research, Inc Multiparticulates of spray-coated drug and polymer on a meltable core
US11116728B2 (en) 2006-11-30 2021-09-14 Bend Research, Inc. Multiparticulates of spray-coated drug and polymer on a meltable core
CA2673458A1 (en) * 2006-12-21 2008-07-03 Mallinckrodt Inc. Composition of and method for preparing orally disintegrating tablets containing a high dose of pharmaceutically active ingredients
ES2758624T3 (es) * 2009-02-12 2020-05-06 Fuji Chem Ind Co Ltd Composición de partículas desintegrantes y material de desintegración rápida moldeado por compresión que comprende la misma
CN102387833B (zh) * 2009-03-20 2016-01-13 因卡伯实验室有限责任公司 固体药物给药设备
US20100285164A1 (en) * 2009-05-11 2010-11-11 Jrs Pharma Orally Disintegrating Excipient
US20160008310A1 (en) * 2014-07-11 2016-01-14 Azanta A/S Misoprostol dispersible tablet
CA2954086C (en) 2014-07-11 2020-03-31 Azanta Danmark A/S Misoprostol dispersible tablet
WO2021174183A1 (en) * 2020-02-27 2021-09-02 Henkel IP & Holding GmbH Encapsulated cleansing composition
CN112618503B (zh) * 2021-01-20 2022-04-15 天津市中央药业有限公司 头孢地尼分散片
CN118903036B (zh) * 2024-10-10 2025-03-04 华夏罕见病药物研发(山东)有限公司 一种含尿苷的组合物的制备方法及其在治疗发育性癫痫性脑病50型中的应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3141875A (en) 1961-03-15 1964-07-21 Fmc Corp Crystallite aggregates disintegrated in acid medium
GB2042888B (en) * 1979-03-05 1983-09-28 Teijin Ltd Preparation for administration to the mucosa of the oral or nasal cavity
US4772473A (en) * 1986-06-16 1988-09-20 Norwich Eaton Pharmaceuticals, Inc. Nitrofurantoin dosage form
US4910023A (en) * 1988-06-09 1990-03-20 Warner-Lambert Company Drug in combination with flavor masking agent and method for making same
HU203041B (en) * 1989-03-14 1991-05-28 Egyt Gyogyszervegyeszeti Gyar Process for producing pharmaceutical compositions of controlled releasing factor containing nifedipin
US5468286A (en) * 1989-10-25 1995-11-21 National Starch And Chemical Investment Holding Corporation Enzymatically debranched starches as tablet excipients
IT1241417B (it) * 1990-03-06 1994-01-14 Vectorpharma Int Composizioni terapeutiche a rilascio controllato di farmaci supportatisu polimeri reticolati e rivestiti con film polimerici,e loro processodi preparazione
CA2041774C (en) 1990-11-27 1994-04-19 Mircea A. Mateescu Use of cross-linked amylose as a matrix for the slow release of biologically active compounds
US5215757A (en) 1991-03-22 1993-06-01 The Procter & Gamble Company Encapsulated materials
US5272191A (en) 1991-08-21 1993-12-21 Fmc Corporation Cold water soluble films and film forming compositions
ATE137668T1 (de) 1992-07-24 1996-05-15 Labopharm Inc Vernetztes polyhydroxyl-material zur enzymatisch gesteuerten arzneistofffreisetzung
US5616343A (en) 1993-03-25 1997-04-01 Labopharm, Inc. Cross-linked amylose as a binder/disintegrant in tablets
US5585115A (en) 1995-01-09 1996-12-17 Edward H. Mendell Co., Inc. Pharmaceutical excipient having improved compressability
US6106865A (en) 1995-01-09 2000-08-22 Edward Mendell Co., Inc. Pharmaceutical excipient having improved compressibility
US5948438A (en) 1995-01-09 1999-09-07 Edward Mendell Co., Inc. Pharmaceutical formulations having improved disintegration and/or absorptivity
IL139728A (en) 1995-01-09 2003-06-24 Penwest Pharmaceuticals Compan Aqueous slurry composition containing microcrystalline cellulose for preparing a pharmaceutical excipient
US5733578A (en) 1995-11-15 1998-03-31 Edward Mendell Co., Inc. Directly compressible high load acetaminophen formulations
TW430561B (en) * 1995-12-20 2001-04-21 Gea Farmaceutisk Fabrik As Rapid release tablet composition comprising tolfenamic acid or a pharmaceutically acceptable salt thereof as active ingredient and a method of preparing such tablet
CA2217238C (en) 1997-10-24 2005-09-20 Louis Cartilier Cross-linked cellulose as a tablet excipient

Also Published As

Publication number Publication date
US20050100600A1 (en) 2005-05-12
AU2004202515A1 (en) 2004-07-01
US20020068084A1 (en) 2002-06-06
WO2001039746A1 (en) 2001-06-07
EP1244428A1 (en) 2002-10-02
US6660303B2 (en) 2003-12-09
BR0016482A (pt) 2002-12-24
AU2061401A (en) 2001-06-12
IL150053A0 (en) 2002-12-01
NO20022645D0 (no) 2002-06-05
KR20020062323A (ko) 2002-07-25
NO20022645L (no) 2002-08-01
HUP0301333A2 (hu) 2004-05-28
CA2393231A1 (en) 2001-06-07
HUP0301333A3 (en) 2005-06-28
AU771440B2 (en) 2004-03-25

Similar Documents

Publication Publication Date Title
MXPA02005562A (es) Superdesintegrante farmaceutico.
HK1029060A1 (en) Pharmaceutical compositions for oral administration, comprising an active substance and a cyclodextrin
GEP20053420B (en) Sustained Release Ranolanolazine Formulation
BG104877A (en) N-substituted anminotetralins as ligands for the neuropeptide y y5 receptor useful in the treatment of obesity and other disorders
TW355683B (en) Composition containing micronized nebivolol
HK1067544A1 (en) Co-processed carbohydrate system as a quick-dissolve matrix for solid dosage forms
AU1729397A (en) Process to prepare soluble delivery systems using volatile salts
CA2289202A1 (en) Solid pharmaceutical formulations containing a physical mixture of sulfoalkyl ether cyclodextrin and a therapeutic agent
MY127980A (en) A pyrrolidineacetamide derivative alone or in combination for treatment of cns disorders
AU2002305099A1 (en) Fatty alcohol drug conjugates
PL346764A1 (en) New oral formulation for 5-ht4
RS49723B (sr) Farmaceutska kompozicija koja sadrži entakapon ili nitekapon kao i umreženi derivat celuloze
DE60019334D1 (de) Antivirale arznei
MXPA03008420A (es) Forma farmaceutica solida oralmente dispersa.
MXPA03002807A (es) Estabilizacion de formulaciones solidas de farmacos.
ZA200108001B (en) Processes for making pharmaceutical oral ECB formulations and compositions.
MXPA06000332A (es) Nueva composicion farmaceutica solida que comprende amisulprida.
MXPA03001227A (es) Composiciones neuroprotectoras de 2-piridinamina y metodos relacionados.
BG105570A (en) Pharmaceutical compositions for modified release insulin sensitiser
MXPA03010672A (es) Composicion para el tratamiento regenerativo de enfermedades del cartilago.
CA2348474A1 (en) Pharmaceutically active composition and dispensing device
HK1045937B (zh) 用於口服間苯三酚的藥物組合物及其製備方法
HK1055260A1 (en) Stabilization of solid thyroid drug formulations
ATE327738T1 (de) Synergistische füllzusammensetzung
GR3019776T3 (en) Antineoplastic medicament containing octadecyl-[2-(N-methylpiperidino)-ethyl] phosphate and synthesis thereof